Blog
-
Beyond the FDA Breakthrough Device Designation: The Work Behind A Scientific Journey
In May 2026, SPOT-MAS 10 received Breakthrough Device Designation from the U.S. Food and Drug Administration, or FDA. Breakthrough Device Designation is not FDA approval, clearance, or marketing authorization. The designation recognizes that the device met the eligibility criteria for participation in FDA’s Breakthrough Devices Program and provides opportunities for more interactive and prioritized engagement with the agency as development continues. The designation was the visible milestone. Less visible was the work required to bring together years of scientific research, clinical evidence, and organizational preparation.Mia Vo - Head of Investor Relations, Mekong Capital - September 14, 2026
